At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|January 10, 2023
2022 SUO Annual Meeting recap: Surgical and nonsurgical approaches to treating bladder cancer
Author(s)Urology Times staff
“[The 2022 Huggins Medal Lecture from Harry Herr, MD] was a fascinating talk, and something that I think anyone could learn from,” says Kelly L. Stratton, MD, FACS.
Advertisement
In this video, Kelly L. Stratton, MD, FACS, recaps a presentation from the 2022 Society of Urologic Oncology Annual Meeting regarding surgical approaches to bladder cancer as well as a lecture given by 2022 Huggins Medal recipient Harry Herr, MD. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5